Molecular Monitoring Is Changing Cancer Care—But Intervention Still Lags

Cancer care is entering a phase where the absence of visible disease no longer confirms therapeutic success. Conventional imaging and clinical assessments often fail to detect microscopic residual disease, leaving clinicians without a reliable method to identify patients at risk of relapse. Molecular residual disease (MRD) testing addresses this gap by using highly sensitive liquid biopsy techniques to detect circulating tumor DNA (ctDNA) that persists after surgery or systemic therapy. By identifying residual cancer signals at the molecular level, MRD testing provides an earlier and more precise indicator of recurrence risk, enabling intervention before clinical progression.

Market Expansion and Diagnostic Sensitivity: From Remission to Measurable Risk

The global MRD market reached an estimated $2.77 billion in 2026 and is projected to exceed $7.7 billion by 2035, reflecting rapid adoption across oncology workflows. These assays can identify one tumor-derived fragment among millions of normal DNA molecules, reframing remission as a probabilistic state rather than a binary outcome.

This shift is occurring against a significant global disease burden. According to the World Health Organization, cancer caused nearly 10 million deaths worldwide in 2020, with lung, colorectal, liver, and breast cancers accounting for the majority of mortality. Recurrence remains a defining challenge, particularly in solid tumors where micrometastatic disease often persists despite apparent clinical remission. In colorectal cancer alone, recurrence rates after curative-intent surgery range from 20% to 30%, underscoring the need for earlier detection of relapse.

Recent findings demonstrated that post-treatment ctDNA positivity strongly predicts recurrence months before radiographic progression. This aligns with a growing body of evidence suggesting that recurrence is not a discrete event, but a measurable biological trajectory.

MRD as a Clinical Decision Driver

MRD is increasingly shaping treatment decisions rather than simply monitoring outcomes. Clinicians are using ctDNA status to guide escalation and de-escalation strategies, allowing therapy to align more closely with individual risk.

Patients with undetectable MRD signals may avoid additional chemotherapy or immunotherapy, reducing exposure to unnecessary toxicity. Conversely, MRD-positive patients can enter early intervention pathways before relapse becomes clinically apparent. This approach is already being tested in colorectal, lung, and breast cancer trials, where MRD status determines eligibility for intensified or maintenance therapies.

This model addresses two persistent inefficiencies in oncology: overtreatment of low-risk patients and delayed intervention in high-risk populations. By quantifying residual disease, MRD introduces a time-sensitive dimension to treatment planning, enabling earlier and more targeted responses.

Clinical Trials Move to Molecular Endpoints

The integration of MRD into clinical trials is reshaping how therapeutic efficacy is measured. Traditional endpoints such as overall survival require long follow-up periods, delaying regulatory decisions and increasing development costs. MRD provides a faster alternative by serving as a surrogate marker for recurrence risk.

In 2025 and 2026, an increasing number of Phase II and III trials incorporated MRD clearance as a primary or secondary endpoint. This approach is particularly prominent in adjuvant and post-surgical settings, where early detection of residual disease can determine long-term outcomes.

Selected MRD-Integrated Clinical Trials (2026)

These studies reflect a broader regulatory and scientific shift toward molecular endpoints. While long-term survival validation remains necessary, MRD-based endpoints are accelerating timelines for drug approval and clinical adoption.

Platform Competition and Strategic Positioning

The MRD field is expanding beyond early leaders into a broader ecosystem of diagnostics firms, sequencing platforms, and clinical laboratories competing to define how recurrence is measured and acted upon.

• In January 2026, Labcorp expanded its MRD portfolio with Plasma Detect and Genome assays targeting breast, lung, and colorectal cancers. The move reflects a strategy to scale MRD testing through existing laboratory infrastructure, allowing broader access in community oncology settings rather than limiting use to specialized centers.
• Quest Diagnostics is advancing its Haystack MRD platform, supported by data to be presented at the 2026 ASCO Gastrointestinal Cancers Symposium. The findings demonstrated ultra-sensitive ctDNA detection in colorectal cancer, positioning the platform for both routine clinical use and integration into biopharma-sponsored trials.
• QIAGEN expanded its MRD capabilities through partnerships with Tracer Biotechnologies and Foresight Diagnostics in 2025. These collaborations focus on NGS-based liquid biopsy assays across solid and hematologic cancers, with an emphasis on decentralized testing and companion diagnostic development.
• Adaptive Biotechnologies has concentrated on hematologic malignancies, scaling its clonoSEQ platform through a collaboration with NeoGenomics. The partnership integrates MRD testing into broader oncology workflows, reinforcing its role in longitudinal disease monitoring rather than one-time assessment.
• Additional entrants are differentiating through technical innovation. Sysmex Inostics, C2i Genomics, and Foresight Diagnostics are developing ultra-sensitive assays targeting rare ctDNA variants. Meanwhile, ArcherDX and Bio-Rad Laboratories are expanding PCR- and NGS-based MRD solutions across research and clinical applications.

Across these developments, the competitive shift is clear. MRD is moving from a niche diagnostic into an integrated platform that connects clinical care, trial design, and drug development.

AI and Longitudinal Monitoring

The next phase of MRD is defined not only by detection sensitivity, but by the ability to interpret molecular signals across time.

Longitudinal monitoring has become central to MRD adoption, as repeated sampling generates datasets that capture tumor evolution rather than static snapshots. Studies presented in 2026 indicate that serial ctDNA measurements significantly improve relapse prediction compared to single timepoint testing, particularly in colorectal cancer trials where MRD is increasingly used as a surrogate endpoint.

Companies are responding by building infrastructure for continuous data interpretation. Platforms are integrating mutation tracking, sequencing depth adjustments, and patient-specific baselines to distinguish transient ctDNA signals from true recurrence. This is particularly important in low-shedding tumors, where signal detection is inherently variable.

AI is increasingly applied to model these trajectories. Rather than relying on binary thresholds, algorithms assess ctDNA kinetics—whether signals are rising, stable, or declining—allowing clinicians to intervene earlier. This approach is already being tested in lung and gastrointestinal cancers, where recurrence risk remains high despite initial treatment response.

The shift is subtle but important. MRD is evolving from a detection tool into a predictive system, where time-series data informs clinical action before disease becomes radiographically visible.

Economic Constraints and Access Gaps

Despite accelerating innovation, MRD adoption remains constrained by cost, reimbursement, and infrastructure limitations.

In the United States, reimbursement is beginning to expand, particularly in colorectal cancer, where Medicare coverage is supporting increased clinical use. However, broader reimbursement across tumor types remains inconsistent, slowing adoption in other indications.

Globally, uptake is uneven. In Europe, regulators continue to require stronger correlations between MRD clearance and long-term survival before approving widespread reimbursement. In Asia, government-backed precision oncology programs are accelerating adoption, but access remains concentrated in major research centers.

Cost remains a central barrier. Tumor-informed MRD assays require individualized sequencing and repeated testing, increasing both complexity and expense. At the same time, health systems must evaluate whether early detection of recurrence offsets the high cost of advanced therapies, which can exceed six figures annually.

To address this, companies are investing in operational efficiency and scale. Sequencing providers and diagnostic labs are expanding automation, standardizing workflows, and developing tumor-agnostic assays that reduce the need for individualized tumor profiling.

Even with these efforts, access remains concentrated in high-resource healthcare systems. As with earlier advances in early detection and targeted therapy, MRD is following a familiar pattern—rapid innovation followed by uneven global distribution.

Closing the Loop: From Detection to Durable Control

Across this series, oncology has shifted from reactive treatment toward an integrated, data-driven system:

• Early detection through liquid biopsy
• Spatial mapping of tumor architecture
• Targeted therapeutic delivery
• Molecular monitoring of residual disease

MRD represents the final layer in this framework. It provides a mechanism to confirm whether treatment has achieved a durable response at the molecular level, transforming “remission” into a measurable endpoint.

This closes a critical gap in precision oncology. Detection identifies disease, spatial biology explains it, and targeted therapies treat it. MRD determines whether those interventions have succeeded.

The remaining challenge is not technical but systemic. For MRD to define the standard of care, it must move beyond specialized centers into routine clinical practice. That transition will determine whether molecular certainty becomes a universal standard—or remains limited to select populations.

Author

Bernice Lottering